Gene Variant Flags Liver Injury Risk From BP Drugs

Adults on blood pressure medication may carry a genetic marker linked to liver injury, though it is not yet used in care.

Updated on Nov. 4, 2026 in Heart Disease

Bold flat-color editorial illustration of a single teal cell-shaped form with a protruding receptor against a cream field.
Researchers identified a genetic variant that appeared in half of liver injury cases tied to blood pressure drugs in a U.S. injury registry. AI Illustration. Upload story photo >

Researchers found that a genetic variant called HLA-B*35:01 appeared in half of liver injury cases linked to antihypertensive drugs in a U.S. injury registry. Adults taking blood pressure medications who carry this variant may be at higher risk of liver injury, though the finding is not yet a clinical screening tool.

Why it matters

Antihypertensive drugs cause only a small share of drug-induced liver injury, but identifying a genetic marker could eventually help clinicians anticipate which patients are more vulnerable. The study points to an immune-driven mechanism that may explain why some patients are affected while most are not.

This registry-based genetic analysis compared 2,207 high-confidence liver injury cases from 2003 to 2024, including 44 linked to antihypertensives. The strong association for HLA-B*35:01 was observed in this registry population, and the study does not establish that screening would prevent injury.

The players

U.S. Drug-Induced Liver Injury Network

A U.S. surveillance registry that tracks serious drug-induced liver injury cases to identify medications and risk factors for patients.

The details

HLA-B*35:01 is a variant in the human leukocyte antigen system, which helps the immune system distinguish the body's own tissues from foreign substances. In this study, carriers developed liver injury sooner after starting treatment, which suggests an accelerated immune response may be involved. The association was particularly strong for methyldopa, an older blood pressure drug that affected young women and consistently caused liver-cell damage.

Timeline

  1. Registry cases were collected between 2003 and 2024.

  2. The antihypertensive liver injury study was published in 2026.

Health Landscape

Drug-induced liver injury is a leading cause of acute liver failure, and most cases are unpredictable with current clinical tools. Genetic markers such as HLA-B*35:01 could eventually support more targeted monitoring for patients starting antihypertensive treatment.

If you take blood pressure medication and notice unexplained fatigue, nausea, yellowing of the skin, or dark urine, contact your doctor promptly. Anyone with questions about their liver health or medication history is encouraged to raise them with their physician rather than change treatment on their own.

The takeaway

Antihypertensive liver injury is uncommon, but this study suggests genetics may eventually help identify who is at higher risk. Discuss any concerns about liver symptoms with your physician, especially if you have a history of unexplained liver problems.

Further reading

For broader context on treatment options, explore our Heart Disease coverage.

Source note: This article includes information reported by News-Medical.